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Abstract
Health care utilization for HIV-1–infected patients appears to be declining in the United States as a result of
highly active antiviral therapy (HAART); yet the opposite appears true in the HIV/hepatitis C virus (HCV)
coinfected population. The reasons for this difference are not well understood. We examined the rates and
reasons for emergency department visits and hospital admissions at an academic tertiary care medical center for
HIV/HCV coinfected patients as compared to HIV-1 monoinfected patients, using a retrospective matched
cohort study design. HIV/HCV coinfected patients had higher rates of health care utilization (emergency
department visits 43.9 versus 7.1 per 100 person-years; hospital admissions 18.2 versus 6.7 per 100 person-years,
for HIV coinfected and monoinfected, respectively). This increase was not solely due to liver related events.
Instead, comorbidities such as diabetes, renal disease, and psychiatric/substance abuse played a larger role in
the health-care utilization in the HIV/HCV coinfected population.
Introduction
Hepatitis C virus (HCV) chronically infects approxima-tely 170 million people worldwide.1 In resource-rich
countries, HCV is the leading cause of end-stage liver disease
(ESLD) and hepatocellular carcinoma (HCC), as well as the
primary indication for liver transplantation.2 In the United
States and Europe, HCV affects 15–30% of HIV-infected
individuals and is a major cause of morbidity and mortality
in the coinfected population.3 Coinfected individuals are re-
ported to have accelerated rates of liver fibrosis, resulting in a
higher risk of ESLD and associated complications including
HCC, when compared to patients with HCV monoinfection.3
Multiple studies projections suggest that the aging of current
HCV-infected patients, largely driven by the baby-boomer
birth cohort, will result in a substantial health and economic
burden over the next decade.4,5 In fact, HCV has surpassed
HIV monoinfection as a cause of death in the United States,
disproportionately affecting the middle-aged.6 Given the
aging HIV population, the health and economic impact of
HIV/HCV coinfected will likely be substantial.
In the era of highly active antiretroviral therapy (HAART),
rates of hospitalization in HIV-1 monoinfected patients first
declined and have since reached a plateau.7 Meanwhile hos-
pitalization rates for HIV/HCV coinfected patients continue
to rise.5,8 HIV/HCV coinfected patients are reported to have
higher rates of hospital admissions, emergency department
visits, and disability days, when compared to their HIV
monoinfected counterparts.5,8 The reasons for these differ-
ences in health-care utilization have not been previously re-
ported. While some studies suggest that liver disease remains
a primary reason for hospitalization in HIV-infected patients,7
this remains controversial.9,10 To better understand the
reasons for health care utilization in HIV/HCV coinfected
patients, we sought to determine the risk factors and reasons
for hospital admissions and emergency department visits in
this high-risk patient population.
Methods
Study population and data abstraction
Patients were recruited from the Infectious Diseases Clinic
at the Duke University Medical Center in Durham, North
Carolina. HIV/HCV coinfected subjects were recruited from
July 2006 to March 2007 for a separate prospective study that
was approved by the Duke Medical Center Institutional Re-
view Board (IRB). A total of 205 patients were identified as
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HCV/HIV coinfected during the study period, and patients
were approached for participation consecutively as they ar-
rived to their clinic appointments. Almost all patients ap-
proached agreed to participate, resulting in a total of 96
coinfected subjects. Patients were at least 18 years of age and
informed consent was obtained from these participants. The
definition of chronic hepatitis C included a positive hepatitis
C antibody and a positive HCV RNA for greater than
6 months. Thus, patients treated for HCV with a sustained
virologic response or who experienced spontaneous clearance
were excluded. HIV-1 monoinfected subjects were selected
from the active clinic patient population and were matched by
age ( – 5 years), gender, year of HIV diagnosis ( – 2 years), and
year first seen in the Infectious Diseases clinic ( – 2 years). IRB-
approved waiver of consent was obtained for inclusion of the
monoinfected participants. We thus created two samples: a
coinfected cohort and a matched HIV-monoinfected cohort.
For all subjects, medical records were retrospectively
reviewed and data were abstracted from January 1996 to
December 2010, by three chart reviewers (S.N., V.A., B.N.).
Data abstraction forms included demographics, comorbid-
ities, CD4 counts, number of and reasons for emergency de-
partment visits and hospital admissions. All subjects were
considered to have a comorbid condition if it was clearly
stated in either the problem list or past medical history of the
infectious diseases clinical encounter note. As part of the
prospective study, all coinfected patients completed an in-
terview with research staff for the collection of social history
data, such as alcohol and drug use. For the monoinfected
subjects this information was abstracted from the problem list
and past medical and social histories of the infectious diseases
clinic notes. Reasons for emergency department visits were
identified by discharge diagnoses documented by the emer-
gency department provider. If there was more than one rea-
son documented, the chart was reviewed and the reason
viewed as most related to the chief complaint was used. In the
case of difficult reconciliation, the reason listed first by the
emergency department provider was used. Reasons for hos-
pital admissions were identified by using only the primary
discharge diagnosis reported by the discharging physician
on the discharge summary. Outcome categories were de-
fined a priori and included (1) HIV associated, (2) non-
HIV–associated infections, (3) liver associated, (4) cardiac
associated, (5) diabetes associated, (6) renal associated, (7)
substance abuse/psychiatric, and (8) other. We used the 1993
Centers for Disease Control and Prevention (CDC) classifi-
cation system for HIV infection to determine which diagnoses
were HIV related. These included AIDS-defining illnesses
such as Pneumocystis jaroveci pneumonia (PCP) and Myco-
bacterium avium complex (MAC), as well as HIV-related in-
fections such as recurrent pneumonia, herpes zoster, candida,
and lymphoma. Liver-associated outcome definitions included
decompensated liver disease (encephalopathy, variceal
bleeding, peritonitis) and transaminitis. Cardiac-associated
outcome definitions included chest pain (unless specifically
noted as noncardiac or musculoskeletal), myocardial infarct,
congestive heart failure, cardiac arrhythmia, or valvular
disease. Diabetes-associated outcomes were defined as
hypoglycemic or hyperglycemic episodes. Renal-associated
outcomes were defined as acute renal failure, initiation of
hemodialysis, missed hemodialysis, and hyperkalemia or
volume overload due to acute or chronic renal disease.
Substance/psychiatric associated outcomes included drug
overdose, intoxication, psychosis, severe depression/anxiety,
and suicide attempts. The ‘‘other’’ category was used to define
an emergency department visit or hospital admission that did
not clearly fit within the previously described categories.
Multiple emergency department visits or hospital admissions
by a unique patient were included.
Statistical analysis
Patient demographic and clinical characteristics were
evaluated with counts and percentages in contingency tables
or with medians and interquartile ranges. Differences be-
tween groups were assessed using the Kruskal-Wallis test for
continuous measures and the Fisher’s exact test for cross-
classifications of categorical data. We compared differences in
the reasons for emergency department visits and hospitali-
zations with counts and percentages and statistical signifi-
cance was estimated with v2 tests. Differences in health care
utilization were evaluated with mean annual rates of emer-
gency department visits and hospitalizations.
We determined the factors that were independently asso-
ciated with rates of health care utilization with multivariable
Poisson models for response variables (1) annual emergency
department visit rate and (2) annual hospitalization rate for
each patient. Predictor variables included the matching vari-
ables (age, gender, years HIV infected, and year first seen at
the Duke Infectious Disease clinic) and other factors previ-
ously associated with health care use (race, HCV infection
status, median CD4 count, drug and alcohol use, diabetes,
and renal disease). All analyses were performed using SAS
version 9.2 (SAS Inc., Cary, NC).
Results
Cohort characteristics
We enrolled 96 patients with HIV/HCV coinfection, mat-
ched to 165 HIV-1 monoinfected subjects. The sample was
predominantly male with a median age of 50 (Table 1). The
HIV monoinfected cohort had a longer duration of HIV in-
fection compared to the coinfected cohort, with medians of 14
and 12 years, respectively ( p = 0.03). Median CD4 count was
slightly lower among the HIV/HCV coinfected (389 versus
486, p = 0.04). There were no differences in CD4 nadir, history
of AIDS-defining illness, diabetes, or hepatitis B coinfection
between the two groups. Coinfected patients were more likely
to be African American, to report active alcohol and illicit
drug use, and to have comorbid renal disease. Sixty-five
percent of the coinfected individuals had federal or need-
based funding (Medicare, Medicaid, Ryan White funding).
Health care utilization
Health care utilization metrics included emergency de-
partment visits and hospital admissions. Over the course
of the study, HIV/HCV coinfected individuals had a median
of 43.9 emergency department visits/100 person-years as
compared to 7.1 emergency department visits/100 person-
years among the HIV monoinfected ( p < 0.0001) group. HIV/
HCV coinfected also had more hospital admissions over the
course of the study as compared to the HIV monoinfected
group (18.2/100 person-years versus 6.7/100 person-years,
p < 0.0001.)
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In multivariable Poisson models, HCV coinfection was
independently associated with a higher rate of emergency
department visits (relative risk [RR] 95% confidence interval
[CI]; 2.07 [1.49, 2.89]; Table 2). This was not true for hospital
admissions, although the trend was toward an increase in
admissions (RR [95% CI]; 1.24 [0.73, 2.09]). In this adjusted
analysis female gender, drug use, and renal disease were
associated with both emergency department visits and hos-
pitalization. In addition black race was independently asso-
ciated with emergency department visits.
The reasons for health care utilization differed between
HIV monoinfected and HIV/HCV coinfected patients. The
primary reasons for emergency department visits in both
cohorts were (1) other and (2) non-HIV–associated infec-
tions (Table 3). However, renal disease, diabetes, psychiatric/
substance abuse, and liver-related emergency department
visits were more common among the HIV/HCV coinfected
group as compared to the monoinfected group ( p = 0.001).
The primary reasons for hospital admissions were ‘‘other’’
and HIV-related admissions for the monoinfected, and ‘‘other’’
and non-HIV associated infections for the HIV/HCV coin-
fected cohort (Table 3). Renal disease, diabetes, psychiatric/
substance abuse, and liver-related causes were again more
common among the HIV/HCV coinfected as compared to
HIV monoinfected ( p < 0.0001) patients. The contribution of
health care utilization due to liver-related events was greater
for the coinfected as compared to the HIV-1 monoinfected
cohort, but liver disease accounted for only a minority of
emergency department visits (1.1%) and hospital admissions
(2.0%). The combination of hospital admissions attributed to
Table 1. Differences in Demographic Characteristics and Health Care Utilization
Between Patients from Each of Two Cohorts
HCV/HCV coinfected HIV monoinfected
n = 96 n = 165
% (n) % (n) p Value
Characteristics
Age, yrs (median, IQR) 50 (45–52) 50 (46–54) 0.13
Male gender 77.1 (74) 75.2 (124) 0.77
Race 0.003
White 30.2 (29) 46.7 (77)
Black 67.7 (65) 46.7 (77)
Other 2.1 (2) 6.7 (11)
Years with HIV (median, IQR) 12 (9–17) 14 (10–19) 0.03
Hx AIDS defining illness 57.3 (55) 52.7 (87) 0.52
CD4 nadir (median, IQR) 144 (35–287) 208 (53–345) 0.16
CD4 median (median, IQR) 389 (269, 561) 487 (320, 670) 0.04
Active ETOH use 30.2 (29) 15.2 (25) 0.005
Active drug use 26 (25) 13.3 (22) 0.012
Hep BsAg positive 1.3 (1) 3.4 (4) 0.65
Diabetes 10.4 (10) 12.1 (20) 0.84
Renal disease 17.7 (17) 7.3 (12) 0.014
Health care utilization
Emergency department visits 43.9/100 person-yrs 7.1/100 person-yrs < 0.0001
Hospital admissions 18.2/100 person-yrs) 6.7/100 person-yrs < 0.001
IQR, interquartile range, 25–75%; HCV, hepatitis C virus.
Table 2. Patient Characteristics Related
to the Risk of Having an Emergency Department





Characteristic Risk ratio p Value Risk ratio p Value
Age 0.91 0.133 0.95 0.329
Black race 2.97 < 0.001 1.64 0.129
Female gender 1.75 0.001 1.83 0.026
CD4 median 1.0 0.171 0.99 0.075
Drug use 3.02 < 0.001 2.22 0.008
ETOH use 0.80 0.224 0.57 0.958
Diabetes 0.97 0.932 1.23 0.558
Renal 2.03 0.012 2.97 < 0.001
HCV coinfection 2.07 < 0.001 1.24 0.430
HCV, hepatitis C virus.
Table 3. Reasons for Health Care Utilization





Reason for visit HIV/HCV HIV HIV/HCV HIV
Total 1134% (#) 658% (#) 345% (#) 329% (#)
Other 57.9 (657) 50.5 (332) 29.3 (101) 38.0 (125)
HIV related 7.0 (79) 11.1 (73) 15.9 (55) 23.4 (77)
Non-HIV
infection
13.4 (152) 19.6 (129) 18.6 (64) 13.4 (44)
Cardiac 5.8 (66) 10.2 (67) 7.5 (26) 15.5 (51)
Diabetes 1.3 (15) 0.91 (6) 2.0 (7) 0.3 (1)
Renal 3.3 (37) 1.5 (10) 9.3 (32) 2.1 (7)
Substance/
psychiatric
10.2 (116) 6.1 (40) 15.4 (53) 7.0 (23)
Liver related 1.1 (12) 0.15 (1) 2.0 (7) 0.3 (1)
p £ 0.001 p < 0.001
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nonliver-related comorbid conditions including substance/
psychiatric disease, renal disease, and diabetes accounted for
almost a third (26.7%) of hospitalizations among the coin-
fected cohort as compared to only 9.4% among the HIV-1
monoinfected cohort.
Discussion
With the advent of HAART, persons with HIV are living
longer.11,12 A decline in AIDS related events and opportu-
nistic infections has led to an increased role for comorbidities
and coinfections in HIV disease burden and health care uti-
lization.12 This study adds to the growing body of evidence
that, when compared to HIV-1 monoinfected individuals,
health care resource utilization is greater for the HIV/HCV
coinfected population. This study also suggests that the rea-
sons for increased health care utilization in this high-risk
group is not solely related to their underlying liver disease,
but is also related to other comorbidities including psychiatric
disease, substance abuse, renal disease, and diabetes.
Previous studies have suggested that liver-related mor-
bidity and mortality have been on the rise in the HIV popu-
lation and that this is primarily driven by chronic HCV
co-infection.13 The D:A:D study identified liver-related deaths
as the most common cause of non-HIV–related mortality.14
In contrast, other studies have reported a reduction in liver-
related mortality among HIV-infected individuals during the
era of HAART, possibly due to improved immune function
attenuating the progression of viral hepatitis.10,15 This study
suggests that the reason for health care utilization among a
coinfected population is not exclusively related to liver mor-
bidity, which comprises 2% or less of emergency department
visits and hospitalizations. This finding is similar to that
reported in the SMART study,16 although the HIV/HCV
coinfected subjects constituted a high proportion of the
nonopportunistic disease death, liver-related mortality was
uncommon. Instead, substance abuse, non-AIDS cancers, and
renal disease comprised a higher proportion of the reasons for
death among this group.16 Here we report that this disparity is
true in health care utilization metrics as well. Although HIV
and other infections were a leading cause of health care uti-
lization in both groups, comorbidities contributed toward a
larger proportion of resource utilization for the HIV/HCV
coinfected patients.
This study has limitations. This is a retrospective chart re-
view and thus only emergency department visits and hospital
admissions occurring at our site would be included. This may
have resulted in an underestimate of utilization in both
groups. The retrospective nature of the study may also result
in bias due to incomplete data collection; as unidentified
confounders may be more common in those with poor health
care follow-up and thus incomplete medical records. The lack
of a reviewer validation process for data abstraction may have
resulted in reviewer specific variations in the classification of
reasons for health care utilization. However, all reviewers
followed definitions outlined a priori when abstracting data,
decreasing the risk of significant variability. Due to the ter-
tiary care structure of our center, the patient population may
include individuals who have more complex health problems
than those seen at community hospitals; thus the results may
not be generalizable to the overall population. On the other
hand, given the patient level data collection, we were able
assess specific reasons for health care utilization and to clas-
sify our HIV/HCV coinfected cohort by evidence of HCV
viremia, establishing an accurate cohort of patients with
chronic hepatitis. Prior studies assessing health care utiliza-
tion have used hepatitis C antibody to identify the HCV-
infected cohort that could result in mischaracterization in up
to 30% of persons who have spontaneously cleared their
infection.
In conclusion, HCV coinfection is a risk factor for increased
health care resource utilization in HIV-infected persons. The
increasing demand of health care resources by this high-risk
group of patients warrants further attention to improve our
knowledge of the reasons for this trend and to consider in-
terventions that may improve long-term clinical outcomes.
This study suggests that comorbid illnesses, in addition to
liver disease, may be contributing to the increased utilization
in HIV/HCV coinfected patients, as compared to their HIV-1
monoinfected counterparts. While larger multicenter studies
are needed to confirm these findings, resource allocation to
address psychiatric disease, substance abuse, and HCV re-
lated medical complications such as diabetes and renal dis-
ease may be helpful to prevent emergency department and
hospital admissions. Access to improved HCV therapies may
improve rates of liver disease, diabetes and renal disease, but
with the prevalence of uncontrolled psychiatric disease and
active substance use noted in this population, it is unlikely
these patients will be viewed as candidates for therapeutic
regimens.17–19 These findings are important to policymakers
and clinicians to determine where we must allocate our time
and resources to be most effective in aiding this unique and
growing population.
Acknowledgments
This work was funded in part by a grant from the Healthy
Community Access Program (HCAP) of the Bureau of
Primary Health Care, of the Health Resources and Services
Administration (HRSA), of the U.S. Department of Health and
Human Services (G92CSO2237-02-02). This work was also
funded in part by the Agency for Healthcare Research and
Quality (AHRQ) Fellowship grant (#T32 HS00079-01-31). We
thank Randall Scott Pollard, LCSW, for participant recruit-
ment and Dr. Vijay Agrawal for his assistance in data collec-
tion for this study.
Abstract Presented at the 47th Annual Meeting of
the Infectious Diseases Society of America, Philadelphia,
Pennsylvania, 2009.
Author Disclosure Statement
No competing financial interests exist.
References
1. Lavanchy D. The global burden of hepatitis C. Liver Int
2009;29(Suppl 1):74–81.
2. Centers for Disease Control and Prevention. Recommenda-
tions for prevention and control of hepatitis C virus (HCV)
infection and HCV-related chronic disease. MMWR (in press).
3. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected
patient. Clin Liver Dis 2003;7:179–194.
4. Wong JB, McQuillan GM, McHutchison JG, Poynard T: Es-
timating future hepatitis C morbidity, mortality, and costs in
the United States. Am J Public Health 2000;90:1562–1569.
544 NORTON ET AL.
5. Grant WC, Jhaveri RR, McHutchison JG, Schulman KA,
Kauf TL. Trends in health care resource use for hepatitis C
virus infection in the United States. Hepatology 2005;42:
1406–1413.
6. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg
SD. The increasing burden of mortality from viral hepatitis
in the United States between 1999 and 2007. Ann Intern Med
2012;156:271–278.
7. Crum-Cianflone NF, Grandits G, Echols S, et al. Trends and
causes of hospitalizations among HIV-infected persons
during the late HAART era: What is the impact of CD4
counts and HAART use? J Acquir Immune Defic Syndr
2010;54:248–257.
8. Linas BP, Wang B, Smurzynski M, et al. The impact of HIV/
HCV co-infection on health care utilization and disability:
Results of the ACTG Longitudinal Linked Randomized
Trials (ALLRT) Cohort. J Viral Hepat (in press).
9. Nunez-Fernandez C, Martin-Carbonero L, Valencia ME,
et al. Liver complications have reached a plateau as cause of
hospital admission and death in HIV patients in Madrid.
AIDS Res Hum Retroviruses 2009;25:383–385.
10. Martin-Carbonero L, Sanchez-Somolinos M, Garcia-
Samaniego J, et al. Reduction in liver-related hospital
admissions and deaths in HIV-infected patients since the
year 2002. J Viral Hepat 2006;13:851–857.
11. Moore RD, Chaisson RE. Natural history of HIV infection in
the era of combination antiretroviral therapy. AIDS 1999;13:
1933–1942.
12. Palella FJ, Jr., Baker RK, Moorman AC, et al. Mortality in the
highly active antiretroviral therapy era: Changing causes of
death and disease in the HIV outpatient study. J Acquir
Immune Defic Syndr 2006;43:27–34.
13. Kramer JR, Giordano TP, Souchek J, El-Serag HB. Hepatitis
C coinfection increases the risk of fulminant hepatic failure
in patients with HIV in the HAART era. J Hepatol 2005;42:
309–314.
14. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related
deaths in persons infected with the human immunodefi-
ciency virus: the D:A:D study. Arch Intern Med 2006;166:
1632–1641.
15. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of anti-
retroviral therapy on liver-related mortality in patients with
HIV and hepatitis C virus coinfection. Lancet 2003;362:1708–
1713.
16. Tedaldi E, Peters L, Neuhaus J, et al. Opportunistic disease
and mortality in patients coinfected with hepatitis B or C
virus in the strategic management of antiretroviral therapy
(SMART) study. Clin Infect Dis 2008;47:1468–1475.
17. Angeli E, Mainini A, Meraviglia P, et al. Eligibility and
feasibility of the treatment of chronic hepatitis C in a Cohort
of Italian HIV-positive patients at a single HIV reference
center. AIDS Patient Care STDs 2011;25:295–301.
18. Swan D, Long J, Carr O, et al. Barriers to and facilitators of
hepatitis C testing, management, and treatment among
current and former injecting drug users: A qualitative ex-
ploration. AIDS Patient Care STDs 2010;24:753–762.
19. Osilla KC, Wagner G, Garnett J, et al. Patient and provider
characteristics associated with the decision of HIV coinfected




Division of Infectious Disease
Duke University Medical Center
Durham, NC 22710
E-mail: brianna.norton@duke.edu
HEALTH CARE UTILIZATION IN HIV/HCV 545
